Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Plasmablastic Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Hodgkin Disease 1HIV Infections 1Glioma 1Glioblastoma 1Burkitt Lymphoma 1Astrocytoma 1

Interventions

Temozolomide 11Radiotherapy 6Lomustine 3Vincristine 2Procarbazine 2Carmustine 2veliparib 1trametinib 1selinexor 1ribociclib 1lonafarnib 1dabrafenib 1carmustine, poliferprosan 20 drug combination 1Watchful Waiting 1Topotecan 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Psychiatric Rehabilitation 1Platelet Count 1Panobinostat 1Neoadjuvant Therapy 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Hydroxychloroquine 1Everolimus 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Glioma × carmustine, poliferprosan 20 drug combination × Clear all
NCT03722355 2019-11-12

Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma

Radiation Therapy Oncology Group

Phase 3 Completed
712 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡